SYFf04fe00c0e79462a96d91a5cf23e76fdRegistry ID: 2025-522505-37-00|Not Yet RecruitingPhase 4
Loading search results
interventional
N/A
1 country
1
The primary objective is to answer the following research question: In adults with non-severe hidradenitis suppurativa (HS) but a high risk of progression to severe disease, does treatment with adalimumab, compared with standard of care (SOC [doxycycline]), reduce the proportion of patients who progress to severe disease over a 104-week period?
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 22, 2026
Actual (reported)The primary outcome: Development of severe HS over a two-year period Endpoint: Percentage of subjects with non-severe HS at baseline who progress to severe HS at any time from baseline (Week 0) until visit 10 (Week 104) in the Adalimumab arm compared with the SOC arm. For this purpose, severe HS will be defined as having either: 1. Hurley stage 3: Multiple interconnected sinus tracts and nodules/abscesses throughout the affected area. or 2. an IHS4 score ≥11 points
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
DOXYCYCLINE
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
TABLET
View registry recordFormulated product
ADALIMUMAB
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
SOLUTION FOR INJECTION
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
DOXYCYCLINE
Named ingredient: Doxycycline
View registry recordADALIMUMAB
Named ingredient: Adalimumab
View registry recordContact the study team to confirm eligibility.
Gentofte Hospital
Hellerup, 2900, Denmark
Rune Kjærsgaard Andersen
First Submitted
May 22, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: